Science / HETS™
A focused model.
A defined research question.
HETS™—Human Engineered Tissue System—is a proposed approach to investigate CKD-associated cardiac injury and fibrosis using engineered human tissues.
- Input / renal context
CKD-associated stress
Uremic, inflammatory and metabolic signals define the disease context.
Renal-module composition and stress preparation: to be specified. - Interface / exposure
Transfer of soluble signals
A defined exposure links the renal context to the cardiac tissue response.
Coupling method, medium compatibility and transfer schedule: open design choices. - Response / cardiac tissue
Engineered myocardial module
Measure remodeling and the response to a reference intervention.
Cell composition, tissue maturity and sampling times: to be specified.
What the study controls
Stress composition and dose, exposure duration, intervention conditions and matched reference conditions. Values are agreed before execution.
What the study measures
Function: contractility and relaxation. Structure: fibrosis and matrix organization. Molecular response: selected secreted factors and signatures.
The proposed research use
Investigate whether a defined CKD-associated stress condition produces a reproducible cardiac remodeling phenotype, and whether an intervention modifies that phenotype.
Why combine these measurements?
The design aims to connect functional response with structural and molecular changes. A single response signal would not, on its own, establish a meaningful disease phenotype or distinguish rescue from nonspecific toxicity.
Where Corelia Intelligence fits
Corelia Intelligence, Corelia Bio’s AI-based research workspace, supports the step before experimental work: organizing and reviewing the existing evidence behind a partner question, so the study design and its intended decision are documented from the start. Open Corelia Intelligence ↗ (opens in a new tab)
What is still being defined?
Module composition and coupling, exposure conditions, study duration, controls, replication and acceptance thresholds. These will be specified around the partner question before experimental execution.
Model boundaries
The proposed system is not a complete model of human CKD or HFpEF. Clinical predictivity, reproducibility and comparative performance have not been established. It is not offered as a validated clinical diagnostic or a replacement for required safety testing.
Validation plan
Evidence before claims.
Corelia Bio has no integrated HETS™ experimental proof-of-concept data at this stage. The following are planned evaluation gates, not completed results.
- Current
Define the context of use
Partner discovery, written scope, one research decision and predefined acceptance criteria.
- Gate 01
Baseline robustness
Establish stable modules and assess variability against prespecified thresholds.
- Gate 02
Disease phenotype and specificity
Test whether remodeling is reproducible and distinguishable from nonspecific toxicity.
- Gate 03
Intervention responsiveness
Test whether a reference intervention partially normalizes the phenotype.
- Gate 04
Translational relevance
Assess alignment with relevant clinical or partner data before claiming decision utility.
Our target is a first physical evidence package in Q1 2027, subject to funding, partner scope and experimental readiness.
HETS™ is intended for a focused cardio-renal context of use. Its potential value will need to be assessed against the models and assays appropriate to each partner’s decision.
- Human tissue context
- Intended to examine human cellular responses; tissue maturity and disease representation remain validation questions.
- Controlled exposure
- Intended to isolate selected stress-response relationships; it will not reproduce the full systemic physiology of a patient.
- Integrated readouts
- Intended to link function, structure and molecular response; repeatability and added decision value must be demonstrated.
Comparative evaluation will be designed around the partner’s intended use.
Example partner deliverable
A study scope you can evaluate.
Illustrative outline for discussion. It contains no experimental results or committed study specifications.
- Research question
- Does a candidate intervention modify a CKD-associated cardiac remodeling phenotype?
- Study conditions
- Baseline tissue; stress-exposed tissue; stress plus reference intervention; stress plus candidate intervention. Include vehicle-matched conditions where applicable.
- Controls and interpretation
- Assess tissue viability alongside the remodeling phenotype. Define controls to distinguish an informative response from nonspecific toxicity.
- Endpoints
- Proposed primary domain: functional response. Supporting domains: matrix remodeling, viability and a focused molecular panel. Select exact assays during scoping.
- Acceptance criteria
- Prespecify baseline variability, phenotype reproducibility, viability boundaries and reference-response requirements. Numerical thresholds and replication are agreed before data collection.
- Decision rule
- If model-quality criteria pass, assess the candidate against the agreed response criteria. If model-quality criteria fail, refine the model before drawing a candidate conclusion.
- Partner receives
- A written context of use, study-condition matrix, endpoint plan, acceptance criteria and decision framework. Experimental reporting is scoped separately.
- Open scoping items
- Materials, exposure and sampling schedule, replication, analysis plan, responsibilities, fees, confidentiality and IP terms.
Founder research
Selected publications.
Ronald St-Louis is a co-author on these publications. They describe prior research and expertise, not Corelia-generated data or validation of HETS™.
- 2022 · JCI Insight
Regeneration of glomerular metabolism and function by podocyte pyruvate kinase M2 in diabetic nephropathy
Co-authored research on kidney metabolism and functional recovery; relevant to the founder’s experience connecting mechanism and phenotype.
- 2019 · Diabetes Care
Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic Nephropathy
Co-authored research examining metabolic changes in diabetic kidney disease, including human glomerular samples.
- 2015 · American Journal of Hypertension
Inflammatory cytokines and reactive oxygen species as mediators of chronic kidney disease-related vascular calcification
Co-authored preclinical work on inflammation, oxidative stress and vascular changes in CKD.
Further context
A transparent foundation.
For broader context on human-relevant methods, see the FDA overview of New Approach Methodologies. It does not constitute endorsement or validation of HETS™.
This non-confidential overview reflects the current proposed design. Detailed study specifications are developed through scoping.
Discuss the scientific approach ↗